Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $73.84: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Ionis Pharmaceuticals is a fully integrated commercial-stage biotech with seven marketed RNA-targeted medicines treating rare and serious diseases, including SPINRAZA and QALSODY (Biogen-partnered) and independently commercialized TRYNGOLZA and DAWNZERA. Revenue was $944M in... Read more
Sell if holding. Engine safety override at $73.84: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Ionis Pharmaceuticals, Inc.
Latest news
- Citigroup Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $115 — benzinga May 19, 2026 positive
- Why Is Biogen Stock Falling Thursday? — benzinga May 14, 2026 neutral
- Biogen's Topline Data From Phase 2 CELIA Study Of Diranersen (BIIB080) For Early Alzheimer's Disease Shows Reductions In — benzinga May 14, 2026 positive
- GSK Targets China's Hepatitis B Market Through New Deal — benzinga May 11, 2026 neutral
- RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100 — benzinga Apr 30, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyBiogen10-K Item 1A: 'We depend on our collaborations with Biogen for the development and commercialization of SPINRAZA and QALSODY.'
Material Events(8-K, last 90d)
- 2026-03-09Item 5.02LOWB. Lynne Parshall and Lead Independent Director Joseph H. Wender both notified the Company on March 3, 2026 they will retire from the Board and not seek re-election at the 2026 Annual Meeting. Peter N. Reikes announced as new director appointee. No disagreements cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $73.84: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $69.03. Score 5.2/10, moderate confidence.
Take-profit target: $91.24 (+23.6% upside). Prior stop was $69.03. Stop-loss: $69.03.
Concentration risk — Counterparty: Biogen; Quality below floor (1.8 < 4.0).
Ionis Pharmaceuticals, Inc. trades at a P/E of N/A (forward -118.7). TrendMatrix value score: 5.5/10. Verdict: Sell.
31 analysts cover IONS with a consensus score of 4.1/5. Average price target: $101.
What does Ionis Pharmaceuticals, Inc. do?Ionis Pharmaceuticals is a fully integrated commercial-stage biotech with seven marketed RNA-targeted medicines...
Ionis Pharmaceuticals is a fully integrated commercial-stage biotech with seven marketed RNA-targeted medicines treating rare and serious diseases, including SPINRAZA and QALSODY (Biogen-partnered) and independently commercialized TRYNGOLZA and DAWNZERA. Revenue was $944M in 2025; key revenue streams include product sales and royalties from partnered drugs.